<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653910</url>
  </required_header>
  <id_info>
    <org_study_id>TJMZK20180713</org_study_id>
    <nct_id>NCT03653910</nct_id>
  </id_info>
  <brief_title>Effect-site Concentration of Remifentanil for Double-lumen Tubes Intubation: Airtraq VS Macintosh Laryngoscope</brief_title>
  <official_title>Effect-site Concentration of Remifentanil for Inhibiting Cardiovascular Responses to Double-lumen Tube Intubation With Airtraq Videolaryngoscopy: a Comparative Study With Macintosh Laryngoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 50% effective concentration of remifentanil by target controlled infusion was not
      determined for inhibiting the haemodynamic response during double-lumen tube (DLT)
      intubation. Previous study showed that Airtraq videolaryngoscope provided more stable
      haemodynamics than Macintosh for double-lumen tube intubation. In this study, the
      investigators will compare the 50% effective concentration of remifentanil between Airtraq
      videolaryngoscope and Macintosh laryngoscope for inhibiting haemodynamic responses during DLT
      intubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dixon &quot;up-and-down&quot; method was used to determine 50% effective concentration of remifentanil
      by target controlled infusion for inhibiting the haemodynamic responses during DLT intubation
      with Airtraq videolaryngoscope or Macintosh laryngoscope.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Actual">May 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remifentanil TCI effect site concentration</measure>
    <time_frame>through study completion, an average of 20 min</time_frame>
    <description>preestablish remifentanil TCI effect site concentration(ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation</time_frame>
    <description>mean arterial pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation</time_frame>
    <description>heart rate in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotrend index</measure>
    <time_frame>at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation</time_frame>
    <description>Narcotrend index in Arabic numerals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hemodynamic Instability</condition>
  <condition>Intubation Complication</condition>
  <arm_group>
    <arm_group_label>Airtraq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received DLT intubation by Airtraq videolarygoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macintosh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received DLT intubation by Macintosh laryngoscope</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Airtraq</intervention_name>
    <description>Airtraq is a kind of videolaryngoscope for intubation</description>
    <arm_group_label>Airtraq</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macintosh</intervention_name>
    <description>Macintosh is a traditional laryngoscope for intubation</description>
    <arm_group_label>Macintosh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterias:

          1. American Society of Anesthesiologists physical status of I-II

          2. Patients aged 18-65 years

          3. BMI 18-35 kg/m2

          4. Elective pulmonary surgery under general anesthesia to double-lumen tubes intubation

          5. Mallampati classifications Ⅰ-Ⅱ

        Exclusion Criterias:

          1. Emergency operation

          2. Anticipated difficult airway or history of intubation difficulties

          3. Be allergic to any of the drugs used in the experiment, or have a history of drug
             allergy

          4. Preoperative use of analgesic, sedative and other drugs

          5. Uncontrolled hypertension and heart disease

          6. Have a history of heavy smoking and alcohol abuse, serious drug abuse, and severe
             systemic infections

          7. There are severe mental and nervous system symptoms, and patients cannot cooperate
             with the study, such as language comprehension disorder, mental illness, etc

          8. Other clinical trials were conducted within 3 months prior to inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ailin Luo, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>alluo@tjh.tjmu.edu.cn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>May 18, 2019</last_update_submitted>
  <last_update_submitted_qc>May 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Wenlong Yao</investigator_full_name>
    <investigator_title>M.D,PhD</investigator_title>
  </responsible_party>
  <keyword>double-lumen tube intubation</keyword>
  <keyword>remifentanil</keyword>
  <keyword>target controlled infusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

